OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit
背景（Background）
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.
原理（Assay Principles）
This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new OX40 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human OX40 to immobilized human OX40 Ligand in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated OX40 protein, a human OX40 Ligand protein, an anti-OX40 neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.
Your experiment will include 4 simple steps:
a) Coat the plate with human OX40 Ligand.
b) Add your molecule of interest to the tests.
c) Add Biotinylated Human OX40 to bind the coated OX40 Ligand.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
e) Finally, the half maximal inhibitory concentration (IC50) of your compound to OX40 : OX40 Ligand binding will be determined by comparing OD readings among different experimental groups.
應(yīng)用說(shuō)明（Application）
This kit is developed for screening for inhibitors of human OX40 binding to human OX40 Ligand.
It is for research use only.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
存儲(chǔ)（Storage）
Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
關(guān)鍵字： OX40 ELISA Kit;OX40試劑盒;OX40 ELISA試劑盒;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。